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Abstract
Background: The optimal treatment of early stage follicular Lymphoma is a matter of debate. Radiation therapy
has frequently been applied with a curative approach beside watchful waiting. Involved field, extended field and
total nodal radiation techniques are used in various protocols, but the optimal radiation field still has to be
defined. Follicular lymphoma is characterized by stable expression of the CD20 antigen on the tumour cells surface.
The anti CD20 antibody Rituximab (Mabthera
®) has shown to be effective in systemic therapy of FL in primary
treatment, relapse and maintenance therapy.
Methods/design: The MIR (Mabthera
® and Involved field Radiation) study is a prospective multicenter trial
combining systemic treatment with the anti CD20 antibody Rituximab (Mabthera
®) in combination with involved
field radiotherapy (30 - 40 Gy). This trial aims at testing the combination’s efficacy and safety with an accrual of 85
patients.
Primary endpoint of the study is progression free survival. Secondary endpoints are response rate to Rituximab,
complete remission rate at week 18, relapse rate, relapse pattern, relapse free survival, overall survival, toxicity and
quality of life.
Discussion: The trial evaluates the efficacy of Rituximab to prevent out-filed recurrences in early stage nodal
follicular lymphoma and the safety of the combination of Rituximab and involved field radiotherapy. It also might
show additional risk factors for a later recurrence (e.g. remission state after Rituximab only).
Trial Registration: ClinicalTrials (NCT): NCT00509184
Background
Worldwide, follicular lymphoma (FL) is the second most
common type of non-Hodgkin’s lymphoma (NHL) [1]
with a rapidly increasing incidence in the last decades
[2]. In the group of indolent lymphomas, FL is the most
common type with 70% of cases. FL tumor cells are
characterized by the translocation t (14;18)(q32;q21)and
invariably express the CD20 antigen. The WHO Classifi-
cation differentiates between grade I, II and III follicular
lymphoma in respect to the number of centroblasts in
the visual microscopy field. FL grade III is often
regarded as an aggressive lymphoma and treated accord-
ingly. Most patients are diagnosed in advanced disease
stage and cannot be cured with conventional therapy.
However, 15-30% patients are diagnosed in the limited
Ann Arbor stages I and II and are potential candidates
for a curative treatment approach. Standard of treatment
for patients with limited disease with a curative inten-
tion is radiotherapy. However, no consensus of the
required radiation field has been reached. Table 1
depicts the results of various radiotherapy trials in FL
lymphoma in stage I and II. Most of the trials are retro-
spective analysis. Involved field (IF), extended field (EF)
and total nodal (TN) irradiation techniques have been
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between 38% and 72% and the 10 year overall survival
ranged in between 50% and 78%. Median survival was
above 12 years, however, in some of the international
trials which categorized lymphomas according to the
Working Formulation also FL grade III and mantle cell
lymphoma were part of the analysis. Forty-one percent
of the patients had a relapse after 8 years in a prospec-
tive German observation trial with 117 patients with
early stage FL who were treated with EF or TN. In stage
I patients, there was no relapse in the irradiation field
after 7 years, but 15% out of filed relapses. This trial led
to the conclusion that large volume radiation techniques
may prevent relapses. However, as extensive radiation
protocols are associated with significant toxicities, grade
3a n dg r a d e4a d v e r s ee v e n t sc o n c e r n i n gt h eh e m a t o -
poietic system were observed in 22% of patients [3].
There have been several studies which combined
radiation therapy with systemic chemotherapy in early
stage FL. Most studies failed to demonstrate a benefit of
combined therapy [4-7]. In one study, the sequential
administration of COP, CHOP-B and involved field irra-
diation improves relapse free survival, but not overall
survival in comparison to historical cohort. Relapse free
survival after 10 years was 72%, however 22% of patients
experienced a grade IV neutropenia and 14 secondary
malignancies were observed [8,9].
The monoclonal chimeric anti CD 20 antibody Rituxi-
mab has revolutionized the treatment of FL in the last
decade. The pivotal phase II trial tested Rituximab
monotherapy in 37 patients with refractory or relapsed
FL. The overall response rate (ORR) was 46% with 8%
complete responses (CR). The median time to progres-
sion (TTP) reached 10.2 months [10]. These promising
results as well as other phase II clinical trials demon-
strated a significant single agent activity of Rituximab in
pretreated as well as in previously untreated patients
with FL [11-13]. In combination with CHOP che-
motherapy, Rituximab induced responses in all evaluable
patients with a complete remission (CR) rate of 63% and
a median PFS of 82 months in a Phase II trial [14].
These results were confirmed in four prospective rando-
mised phase III studies investigating Rituximab in com-
bination chemotherapy versus chemotherapy alone in
first line therapy which showed significant increase in
initial response rates, a significant prolongation of
response duration and a significantly longer overall sur-
vival [15-18]. Rituximab was added to FCM (Fludara-
bine, Cyclophosphamde, Mitoxantrone) chemotherapy
in relapsed FL in a prospective randomized Phase III
trial and showed a significantly longer PFS and OS com-
pared with FCM alone [19]. In addition to the impress-
ing results of Rituximab as part of first line and relapse
treatment, Rituximab maintenance therapy is effective in
relapsed FL [20-22]. Rituximab maintenance therapy has
also been shown to prolong PFS after first line therapy
in two prospective randomized trials [23,24].
In the context of radiotherapy, the high efficacy of
Rituximab in systemic treatment suggests that this drug
may be of benefit in the eradication of minimal disease
outside the radiation field. This concept is in line with
the observation that Rituximab contributes to the
elimination of minimal residual disease after cytotoxic
therapy [25-27]. In addition, Rituximab may enhance
radiosensitivity of lymphoma cells and may thus
improve the efficacy of radiotherapy [28,29].
Methods/Design
Trial organization
The MIR trial has been designed by the Trial Center of
the Department of Radiation Oncology and the Depart-
ment of Internal Medicine in cooperation with the Ger-
man Study Group for Low Grade Lymphoma (GLSG).
The trial is an investigator initiated trial. Sponsor of the
trial is the University Hospital of Heidelberg.
The trial is coordinated by the Department of Radiation
Oncology of the University of Heidelberg in cooperation
with the GLSG. The Dept. of Radiation Oncology is
responsible for overall trial management, trial registration
ClinicalTrials.gov Identifier: NCT00509184), database
management, quality assurance including monitoring,
reporting and for the scientific program of all trial related
meetings.
A total of 15 centers in Germany participate in this
trial. The centers are (listed alphabetically): University-
hospital Charité, Berlin; HELIOS Hospital, Berlin-Buch;
Universityhospital Dresden, Universityhospital Essen;
Universityhospital Göttingen; Universityhospital Hann-
over; Universityhospital Heidelberg; Universityhospital
Cologne; Universityhospital Mainz; Universityhospital
Mannheim; Universityhospital Marburg; Universityhos-
pital Munich LMU; Universityhospital Munich TU;
Universityhospital Ulm.
On-site monitoring
During recruitment of patients monitoring on site is
performed according to good clinical practice (GCP)
guidelines. The data management will be performed by
the Coordination Centre for Clinical Trials (KKS) of the
University of Heidelberg.
Ethics, informed consent and safety
The final protocol was approved by the ethics commit-
tee of the University of Heidelberg, Medical School
(AFmu-085/2007, http://www.klinikum.uni-heidelberg.
de) and the Paul-Ehrlich-Institute (PEI-registration
number 432/06). This study complies with the Helsinki
Declaration in its recent German version, the Medical
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ples of Good Clinical Practice (GCP) guidelines and the
Federal Data Protection Act. The trial will also be car-
ried out in keeping with local legal and regulatory
requirements. The medical secrecy and the Federal Data
Protection Act will be followed.
Written informed consent is obtained from each
patient in oral and written form before inclusion in the
trial and the nature, scope, and possible consequences
of the trial have been explained by a physician. The
investigator will not undertake any measures specifically
required only for the clinical trial until valid consent has
been obtained.
Study design and endpoints
T h eM I Rs t u d yi sap r o s p e c t i v ep h a s eI Is t u d yc o m b i n -
ing systemic Rituximab therapy with involved field irra-
diation in patients with FL WHO Grad 1 and 2 in Stage
I and II.
This trial aims at testing the combination’se f f i c a c y
and toxicity with an accrual of 85 patients.
Primary endpoint of the study is progression free sur-
vival (2 years). Secondary endpoints are complete remis-
sion rate after Rituximab monotherapy (week 7) and
after complete treatment (week 18), relapse rate, relapse
pattern, relapse free survival, overall survival, toxicity
and quality of life.
Patient selection
In order to be included in the MIR trial, patients (18 to
75 years) are required to have pathologically documen-
ted FL Who grade 1 or 2 in Ann Arbor Stage I or II.
The histology has to be confirmed by one of the
reference pathologists of the GLSG. Evaluation of CD20
status is compulsory. Maximal tumour diameter is 7 cm.
Accrued patients will be expected to demonstrate suffi-
cient compliance, they should also live in relative proxi-
mity of the centre of care to ensure adequate follow-up
after treatment. In addition, adequate haematological
function is essential for inclusion in the trial (leukocytes
≥ 3000 × 10
3 /ml, platelets ≥ 100000 × 10
3 /ml, and
haemoglobin ≥ 10 g/dL). Patients are required to use
adequate contraception during and at least up to
3 months after treatment. Naturally, written informed
consent is obtained prior to commencement of
treatment in this trial.
Patients are not eligible with previous irradiation, che-
motherapy of immunotherapy. Patients with severe con-
current systemic disease or other malignant disease
(apart from cervical carcinoma in-situ, basal cell carci-
noma, or unless previously treated and in remission for
≥ 5 years without further treatment) can also not be
included in this trial. Furthermore, clinical performance
worse than ECOG 2, bulky disease (> 7 cm), splenic
involvement, immunodeficiency, viral hepatitis, collage-
nosis, severe psychiatric illness, hypersensitivity to for-
eign proteins will prohibit inclusion as will pregnancy or
breast feeding.
Statistical Design
The hypothesis states an improvement of the progression
free survival after 2 years from 75% to 89% (risk reduc-
tion by 40% using Rituximab). 77 patients have to be
evaluated to proof the hypthesis with a 95% power using
a single arm binomial test. An additional 8 patients have
to be recruited for a possible 10% drop-out rate.
Work up
Patients with pathologically documented nodal FL Who
grade 1 or 2 in stage I or II receive a complete work-up
including, cervical, thoracic, abdominal and pelvic CT
scans, bone marrow histology and extensive laboratory
testing. An ENT examination is mandatory for supra
diaphragmal disease and a kidney function test for
abdominal disease. The FLIPI risk score will be calcu-
lated for each patient. All in- and exclusion criteria are
examined. In the event of patients meeting the required
inclusion criteria, information about participation in the
study with possible risks andb e n e f i t si sg i v e nt ot h e
patients and written informed consent is obtained. In
the event of patients declining treatment within the
MIR trial, irradiation alone is offered.
Treatment
The treatment lasts over 12 weeks and is divided in 3
sections as illustrated in Figure 1. The first section con-
sists of 4 weekly i.v. infusions of Rituximab (Roche AG,
Basel, Switzerland) at a standard dosage of 375 mg/m
2
given on day 1, 8, 15 and 22. There is a 4 week treat-
ment break thereafter (week 5 - 8) which includes a
radiation therapy planning CT of the involved body
region in week 7. Response to the Rituximab therapy is
also evaluated at this time. Another 4 weekly infusions
of Rituximab are administered in week 9-12. At the
Figure 1 Study Schema of the MIR trial (IF = involved-field;
f/u = follow up).
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region is applied, a three dimensional radiation planning
is compulsory for all patients having abdominal or retro-
peritoneal disease. Involved field irradiation consists of a
dose of 30 Gy in daily fractions of 2 Gy (Monday to
Friday). Patients who still show enlarged lymph nodes in
week 7 receive additional boost irradiation with a total
dose of 40 Gy. Accepted tolerance doses of organs at
risk must not be exceeded.
Safety and discontinuation of treatment
Toxicities are classified by grade, type, duration, onset,
and relationship to study treatment.
Treatment of Rituximab-induced adverse reactions is
carried according to recommendations by the provider.
All patients will receive anti allergic prophylaxis (parace-
tamol, clemastin) and when appropriate, corticosteroids.
In the case of fever (> 38,5°C), chills, bronchial constric-
tion, hypotension (> 30 mm Hg) it is recommended to
discontinue treatment with Rituximab.
Analysis of safety related data is performed with
respect to frequency of:
￿ Serious Adverse Events and Adverse Events stratified
by organ-system
￿ Adverse Events stratified by severity
￿ Adverse Events stratified by causality.
Patient toxicities will be assessed using the NCI Com-
mon Toxicity Criteria (CTC). Toxicity will be evaluated
prior to treatment, weekly prior to each course of infu-
sional Rituximab and at follow-up. Unacceptable toxicity
is defined as unpredictable, or irreversible Grade 4 toxi-
city. Decisions regarding Rituximab dose-adjustment
will be made using the guidelines below and based on
haematological parameters (ANC and platelets) moni-
tored weekly during radiation before each dose of
Rituximab.
Whenever necessary, metoclopramide or 5-HT3-
antagonists are used for antiemesis.
Antihistamines such as clemastine are administered
prior to Rituximab application.
Trial duration
Patient recruitment is planned to be completed after
24 months. Patients will be monitored for two and a
half years after study entry. The total duration of the
trial is estimated to be 4 and a half years. Recruitment
started in March 2008. As of February 2010, 65 patients
have been included in the trial.
Individual exclusion criteria are serious adverse reac-
tions or the patient’s voluntary withdrawal from the trial.
Assessment of therapeutic efficiency
CT or MRI of the involved regions are scheduled for
week 7 and 18. For screening of the whole body stem,
CT or MRI imaging is planned for months 6, 12, 18, 24
and 30 after start of therapy. At all above mentioned fol-
low-up visits, there is also a clinical examination with
palpation of all lymph node sites schedulded.
Local response is evaluated in accordance with the
Cheson Criteria [30].
￿ Complete response (CR) is the complete disap-
pearance of all detectable evidence of disease on CT,
and all disease-related symptoms, and normalization
of biochemical abnormalities, and normal bone mar-
row biopsy (BMB). Previously involved nodes on CT
more than 1.5 cm in their greatest axial diameter
must regress to less than 1.5 cm, and previously
measured nodes of 1.1-1.5 cm must decrease to less
than 1 cm.
￿ CRu (uncertain) corresponds to CR criteria but
with a residual mass more than 1.5 cm in greatest
axial diameter that has regressed by more than 75%.
￿ Partial response (PR) is at least 50% reduction in
the sum of the product of the greatest diameters
(SPD) of the six largest nodes with no increase in
the size of other nodes and no new sites of disease.
Splenic and hepatic nodules must regress by at least
50% in the SPD.
￿ Stable disease (SD) is less than a PR but is not
progressive disease. Progressive disease (PD) is more
than 50% increase in the sum of the product of the
greatest diameters of any previously abnormal node,
or appearance of any new lesions during or at the
end of therapy.
￿ Relapsed disease (RD) is the appearance of any
new lesion or increase in size of more than 50% of
previously involved sites or nodes in patients who
achieved CR or CRu.
Quality assurance program
All staging examinations are reviewed centrally as part
of the quality assurance program. Completeness of the
staging, quality of the imaging and extend of involve-
ment are analysed. In addition, a proposal for the
radiation site is sent out to the treatment centre. All
radiation treatment plans are also centrally reviewed in
a retrospective manner.
Discussion
The MIR trial is evaluating the effectiveness and the
safety of the combination of an involved field radiation
therapy with the systemic anti CD20 antibody Rituximab
for early stage follicular lymphoma grade 1 or 2 in a
multi center setting. It also might show additional risk
factors for a later recurrence (e.g. remission state after
Rituximab only).
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